Cover Image
市場調查報告書

預防疫苗的全球市場

Global Preventable Vaccines Market 2015-2019

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 268751
出版日期 內容資訊 英文 137 Pages
訂單完成後即時交付
價格
Back to Top
預防疫苗的全球市場 Global Preventable Vaccines Market 2015-2019
出版日期: 2015年02月18日 內容資訊: 英文 137 Pages
簡介

所謂疫苗,是刺激人體免疫系統造成對特定疾病的免疫,保護此人不受感染。疫苗通常經由注射,不過,也有口服式和吸入式。疫苗有成人用的,也有兒童、青少年用的,譬如在兒童用的情況,用於給予兒童對白喉、流感、肝炎、肺炎球菌的各種疾病的免疫力。根據美國食品藥物管理局 (FDA) 的分類,「兒童」是0∼21歲,分為新生兒、幼兒、青少年,不過,歐洲藥品管理局 (EMA) 分類著0∼18歲為「兒童」。全球預防疫苗市場,推算2014∼2019年以10.16%的年複合成長率成長。

本報告提供全球的預防用疫苗市場相關分析、整體市場結構、趨勢和研究開發情形、整體及各部門 (兒童用、成人用) 、各地區的市場趨勢 (今後5年分的預測值) 、競爭環境、主要企業簡介 (企業概要、產業策略、業績 (各領域、各地區)、SWOT分析) 等調查評估。

第1章 摘要整理

第2章 簡稱清單

第3章 調查範圍

  • 市場概要
  • 主要的產品

第4章 市場調查手法

  • 市場調查流程
  • 調查手法

第5章 簡介

第6章 疫苗核准流程

第7章 市場形勢

  • 市場概要
  • 市場規模與預測
  • 全球成人用、兒童用預防疫苗的市場佔有率 (實際成果值、預測值)
  • 波特的五力分析

第8章 疫苗的各種類的市場區隔

  • 減毒活病毒疫苗
  • 不活化疫苗
  • 類毒素疫苗
  • 基因改造疫苗

第9章 各產品種類的市場區隔

  • 多糖體疫苗
  • 結合型疫苗

第10章 地區區分

第11章 全球各地區的預防疫苗市場

  • 美國的市場規模與預測
  • 歐洲的市場規模與預測
  • 日本的市場規模與預測
  • 印度的市場規模與預測
  • 中國的市場規模與預測

第12章 全球兒童用預防疫苗市場

  • 全球兒童用預防疫苗市場
  • 全球兒童用預防疫苗市場分類
  • 全球兒童用肝炎疫苗市場
  • 全球兒童用B型流感菌 (Hib) 疫苗市場
  • 全球兒童用MMR (麻疹、腮腺炎、德國麻疹) 疫苗市場
  • 全球兒童用混合疫苗市場
  • 全球兒童用肺炎球菌疫苗市場
  • 全球小兒麻庳疫苗市場
  • 全球兒童用水痘疫苗市場
  • 全球及其他的兒童用疫苗市場
  • 全球兒童用預防疫苗市場:各類型市場佔有率趨勢 (實際成果值、預測值)

第13章 全球成人用預防疫苗市場

  • 市場規模與預測
  • 全球成人用預防疫苗市場分類
  • 全球成人用子宮頸癌症疫苗市場
  • 全球成人用肝炎疫苗市場
  • 全球成人流感疫苗市場
  • 全球成人用肺炎球菌疫苗市場
  • 全球成人用旅行、白喉與破傷風、其他疫苗市場

第14章 主要國家

  • 美國
  • 中國
  • 日本
  • 印度

第15章 購買標準

第16章 市場成長因素

第17章 成長因素與其影響

第18章 市場課題

第19章 成長因素與課題的影響

第20章 市場趨勢

第21章 趨勢與其影響

第22章 業者情勢

  • 競爭模式
    • 主要消息
    • 企業合併、收購 (M&A)
  • 市場佔有率分析
  • 其他卓越供應商

第23章 主要供應商分析

  • GlaxoSmithKline
  • Merck
  • Novartis
  • Pfizer
  • Sanofi

第24章 相關報告

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: IRTNTR5256

About Preventable Vaccines

Vaccines can be defined as a product that stimulates a person's immune system to produce immunity to a specific disease, thereby protecting the person from that disease. According to the CDC, vaccines are usually administered through needle injections, but can also be administered orally or sprayed into the nose. Vaccines can be used for both adults and infants and adolescents. Pediatric vaccines are used for the immunization of children to give protection against various infectious diseases such as diphtheria, influenza, hepatitis, pneumococcal diseases, and meningococcal diseases. According to the classification adopted by the US FDA, children are classified as newborn, infant, and adolescent, ranging from birth to 21 years of age. However, the EMA classifies pediatrics as ranging from birth to 18 years of age.

TechNavio's analysts forecast the Global Preventable Vaccines market to grow at a CAGR of 10.16 percent over the period 2014-2019.

Covered in this Report

This report covers the present scenario and the growth prospects of the Global Preventable Vaccines market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of preventable vaccines. The report examines the market for vaccines used in humans. It covers only commercialized vaccines for diseases that are vaccine preventable.

The report does not cover emerging vaccines for diseases that are not currently vaccine preventable, such as Ebola infection, Epstein-Ban virus infection, Alzheimer's disease, diabetes, Helicobacter pylori infection, multiple sclerosis, Parkinson's disease, or West Nile virus infection.

The report has broadly categorized preventable vaccines into two major segments:

  • Adult Preventable Vaccines
  • Pediatric Preventable Vaccines

TechNavio's report, the Global Preventable Vaccines Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the APAC and EMEA regions; it also covers the Global Preventable Vaccines market landscape and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

Key Regions

  • Americas
  • APAC
  • EMEA

Key Vendors

  • GlaxoSmithKline
  • Merck
  • Novartis
  • Pfizer
  • Sanofi

Other Prominent Vendors

  • Abbott
  • AstraZeneca
  • Bavarian Nordic
  • Baxter
  • Bharat Biotech
  • Bharat Immunologicals and Biologicals
  • bioCSL
  • Bio Med
  • Crucell
  • Dynavax Technologies
  • Indian Immunologicals
  • Janssen Pharmaceuticals
  • Kaketsuken
  • LG Life Sciences
  • Mitsubishi Tanabe Pharma
  • Lupin
  • Nuron
  • Protein Sciences
  • Panacea Biotec
  • Roche
  • Serum Institute of India
  • Shenzhen Kangtai Biological Products
  • Serum Institute of India
  • Sinovac Biotech
  • S K Chemicals
  • Takeda Pharmaceutical
  • Valeant Pharmaceuticals
  • Zydus Cadila

Market Driver

  • Inclusion in NIP
  • For a full, detailed list, view our report

Market Challenge

  • Inadequate Vaccine Coverage
  • For a full, detailed list, view our report

Market Trend

  • Increase in Strategic Alliances
  • For a full, detailed list, view our report

Key Questions Answered in this Report

  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings

04. Market Research Methodology

  • 04.1. Market Research Process
  • 04.2. Research Methodology

05. Introduction

06. Vaccine Approval Process

07. Market Landscape

  • 07.1. Market Overview
  • 07.2. Market Size and Forecast
  • 07.3. Global Adult and Pediatric Preventable Vaccine Market Share 2014-2019
  • 07.4. Five Forces Analysis

08. Market Segmentation by Type of Vaccine

  • 08.1. Live Attenuated Vaccine
  • 08.2. Killed Vaccine
  • 08.3. Toxoid Vaccine
  • 08.4. Genetically Modified/Engineered Vaccine

09. Market Segmentation by Product Type

  • 09.1. Polysaccharide Vaccines
  • 09.2. Conjugate Vaccines

10. Geographical Segmentation

11. Global Preventable Vaccines Market by Key Geographies

  • 11.1. Market Size and Forecast for the US
  • 11.2. Market Size and Forecast for the EU
  • 11.3. Market Size and Forecast for Japan
  • 11.4. Market Size and Forecast for India
  • 11.5. Market Size and Forecast for China

12. Global Pediatric Preventable Vaccines Market

  • 12.1. Global Pediatric Preventable Vaccine Market
    • 12.1.1. Market Size and Forecast
  • 12.2. Market Segmentation of the Global Pediatric Preventable Vaccine Market
  • 12.3. Global Pediatric Hepatitis Vaccines Market
    • 12.3.1. Market Size and Forecast
  • 12.4. Global Pediatric Haemophilus Influenzae Type B (Hib) Vaccines Market
    • 12.4.1. Market Size and Forecast
  • 12.5. Global Pediatric MMR Vaccines Market

Market Size and Forecast

  • 12.6. Global Pediatric Combination Vaccines Market
    • 12.6.1. Market Size and Forecast
  • 12.7. Global Pediatric Pneumococcal Vaccines Market
    • 12.7.1. Market Size and Forecast
  • 12.8. Global Polio Vaccines Market
    • 12.8.1. Market Size and Forecast
  • 12.9. Global Pediatric Varicella Vaccines Market
    • 12.9.1. Market Size and Forecast
  • 12.10. Global Other Pediatric Vaccines Market
    • 12.10.1. Market Size and Forecast
  • 12.11. Global Pediatric Preventable Vaccines Market 2014 and 2019 (by percentage)

13. Global Adult Preventable Vaccines Market

  • 13.1. Market Size and Forecast
  • 13.2. Market Segmentation of the Global Adult Preventable Vaccines Market
  • 13.3. Global Adult Cervical Vaccines Market
    • 13.3.1. Market Size and Forecast
  • 13.4. Global Adult Hepatitis Vaccines Market
    • 13.4.1. Market Size and Forecast
  • 13.5. Global Adult Influenza Vaccines Market
    • 13.5.1. Market Size and Forecast
  • 13.6. Global Adult Pneumococcal Vaccines Market
    • 13.6.1. Market Size and Forecast
  • 13.7. Global Adult Travel, Diphtheria-Tetanus, and Miscellaneous Vaccines Market
    • 13.7.1. Market Size and Forecast

14. Key Leading Countries

  • 14.1. US
  • 14.2. China
  • 14.3. Japan
  • 14.4. India

15. Buying Criteria

16. Market Growth Drivers

17. Drivers and their Impact

18. Market Challenges

19. Impact of Drivers and Challenges

20. Market Trends

21. Trends and their Impact

22. Vendor Landscape

  • 22.1. Competitive Scenario
    • 22.1.1. Key News
    • 22.1.2. Mergers and Acquisitions
  • 22.2. Market Share Analysis 2014
    • 22.2.1. GlaxoSmithKline
    • 22.2.2. Merck
    • 22.2.3. Novartis
    • 22.2.4. Pfizer
    • 22.2.5. Sanofi
  • 22.3. Other Prominent Vendors

23. Key Vendor Analysis

  • 23.1. GlaxoSmithKline
    • 23.1.1. Key Facts
    • 23.1.2. Business Overview
    • 23.1.3. Business Segmentation
    • 23.1.4. Business Segmentation by Revenue 2012 and 2013
    • 23.1.5. Sales by Geography
    • 23.1.6. Pipeline Products
    • 23.1.7. Business Strategy
    • 23.1.8. Key Information
    • 23.1.9. SWOT Analysis
  • 23.2. Merck
    • 23.2.1. Key Facts
    • 23.2.2. Business Overview
    • 23.2.3. Business Segmentation by Revenue 2013
    • 23.2.4. Business Segmentation by Revenue 2012 and 2013
    • 23.2.5. Sales by Geography
    • 23.2.6. Business Strategy
    • 23.2.7. Key Developments
    • 23.2.8. SWOT Analysis
  • 23.3. Novartis
    • 23.3.1. Key Facts
    • 23.3.2. Business Description
    • 23.3.3. Business Segmentation
    • 23.3.4. Revenue by Business Segmentation
    • 23.3.5. Revenue Comparison 2012 and 2013
    • 23.3.6. Sales by Geography
    • 23.3.7. Business Strategy
    • 23.3.8. Key Developments
    • 23.3.9. SWOT Analysis
  • 23.4. Pfizer
    • 23.4.1. Key Facts
    • 23.4.2. Business Overview
    • 23.4.3. Business Segmentation by Revenue 2013
    • 23.4.4. Business Segmentation by Revenue 2012 and 2013
    • 23.4.5. Geographical Segmentation by Revenue
    • 23.4.6. Business Strategy
    • 23.4.7. Key Developments
    • 23.4.8. SWOT Analysis
  • 23.5. Sanofi
    • 23.5.1. Key Facts
    • 23.5.2. Business Description
    • 23.5.3. Business Segmentation
    • 23.5.4. Revenue by Business Segmentation
    • 23.5.5. Revenue Comparison 2012 and 2013
    • 23.5.6. Sales by Geography
    • 23.5.7. Business Strategy
    • 23.5.8. Key Developments
    • 23.5.9. SWOT Analysis

24. Other Reports in this Series

List of Exhibits

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Vaccine Approval Process
  • Exhibit 3: Global Preventable Vaccines Market 2014-2019 (US$ million)
  • Exhibit 4: Global Preventable Vaccines Market Categories
  • Exhibit 5: Global Adult and Pediatric Preventable Vaccine Market Share 2014-2019 (US$ million)
  • Exhibit 6: Global Preventable Vaccines Market Share by Vaccine Type 2014 and 2019
  • Exhibit 7: Global Preventable Vaccines Market Segmentation by Type of Vaccine
  • Exhibit 8: Global Preventable Vaccines Market Segmentation by Product Type
  • Exhibit 9: Global Preventable Vaccines Market by Geographical Segmentation 2014
  • Exhibit 10: Global Preventable Vaccines Market by Region 2014-2019 (US$ million)
  • Exhibit 11: Global Preventable Vaccines Market in the US 2014-2019 (US$ million)
  • Exhibit 12: Global Preventable Vaccines Market in the EU 2014-2019 (US$ million)
  • Exhibit 13: Global Preventable Vaccines Market in Japan 2014-2019 (US$ million)
  • Exhibit 14: Global Preventable Vaccines Market in India 2014-2019 (US$ million)
  • Exhibit 15: Global Preventable Vaccines Market in China 2014-2019 (US$ million)
  • Exhibit 16: Global Pediatric Preventable Vaccines Market 2014-2019 (US$ million)
  • Exhibit 17: Global Pediatric Preventable Vaccines Market Segmentation
  • Exhibit 18: Global Pediatric Hepatitis Vaccines Market 2014-2019 (US$ million)
  • Exhibit 19: Global Pediatric Haemophilus Influenzae Type B Vaccines Market 2014-2019 (US$ million)
  • Exhibit 20: Global Pediatric MMR Vaccine Market 2014-2019 (US$ million)
  • Exhibit 21: Global Pediatric Combination Vaccines Market 2014-2019 (US$ million)
  • Exhibit 22: Global Pediatric Pneumococcal Vaccines Market 2014-2019 (US$ million)
  • Exhibit 23: Global Polio Vaccines Market 2014-2019 (US$ million)
  • Exhibit 24: Global Pediatric Varicella Vaccines Market 2014-2019 (US$ million)
  • Exhibit 25: Global Other Pediatric Vaccines Market 2014-2019 (US$ million)
  • Exhibit 26: Global Pediatric Preventable Vaccines Market by Vaccine Segmentation (2014 and 2019) (US$ Million)
  • Exhibit 27: Global Pediatric Preventable Vaccines Market by Vaccine Segmentation 2014 (in %)
  • Exhibit 28: Global Pediatric Preventable Vaccines Market by Vaccine Segmentation 2019 (in %)
  • Exhibit 29: Snapshot of Global Pediatric Preventable Vaccines Market by Segments 2014-2019
  • Exhibit 30: Global Adult Preventable Vaccines Market 2014-2019 (US$ million)
  • Exhibit 31: Global Adult Cervical Vaccines Market 2014-2019 (US$ million)
  • Exhibit 32: Global Adult Hepatitis Vaccines Market 2014-2019 (US$ million)
  • Exhibit 33: Global Adult Influenza Vaccine Market 2014-2019 (US$ million)
  • Exhibit 34: Global Adult Pneumococcal Vaccines Market 2014-2019 (US$ million)
  • Exhibit 35: Global Travel, Diphtheria-Tetanus, and Miscellaneous Vaccines Market 2014-2019 (US$ million)
  • Exhibit 36: Global Adult Preventable Vaccines Market by Vaccine Segmentation (2014 and 2019) (US$ Million)
  • Exhibit 37: Global Adult Preventable Vaccines Market by Vaccine Segmentation 2014 (in %)
  • Exhibit 38: Global Adult Preventable Vaccines Market by Vaccine Segmentation 2019 (in %)
  • Exhibit 39: Snapshot of Global Adult Preventable Vaccines Market by Segments 2014-2019
  • Exhibit 40: Buying Criteria of the Global Preventable Vaccines Market
  • Exhibit 41: Drivers and their Impact on the Key Customer Category of the Global Preventable Vaccines Market
  • Exhibit 42: Drivers and their Impact on Geographies in Global Preventable Vaccines Market
  • Exhibit 43: GlaxoSmithKline's Revenue 2013
  • Exhibit 44: GlaxoSmithKline: Vaccine Pipeline
  • Exhibit 45: Merck's Revenue 2013
  • Exhibit 46: Novartis' Revenue 2013
  • Exhibit 47: Novartis: Vaccine Pipeline
  • Exhibit 48: Pfizer's Revenue 2013
  • Exhibit 49: Sanofi's Revenue 2013
  • Exhibit 50: GlaxoSmithKline: Business Segmentation 2013
  • Exhibit 51: GlaxoSmithKline: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
  • Exhibit 52: GlaxoSmithKline: Sales by Geography 2013
  • Exhibit 53: GlaxoSmithKline: Pipeline Products 2013
  • Exhibit 54: Merck & Co. Inc.: Business Segmentation by Revenue 2013
  • Exhibit 55: Merck & Co. Inc.: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
  • Exhibit 56: Merck & Co. Inc.: Sales by Geography 2013
  • Exhibit 57: Novartis AG: Business Segmentation
  • Exhibit 58: Novartis AG: Revenue by Business Segmentation 2013
  • Exhibit 59: Novartis AG: Revenue by Business Segmentation 2012 and 2013 (US$ million)
  • Exhibit 60: Novartis AG: Revenue by Geographical Segmentation 2013
  • Exhibit 61: Pfizer: Business Segmentation by Revenue 2013
  • Exhibit 62: Pfizer: Business Segmentation by Revenue 2012 and 2013
  • Exhibit 63: Pfizer: Geographical Segmentation by Revenue 2013
  • Exhibit 64: Sanofi SA: Business Segmentation
  • Exhibit 65: Sanofi SA: Revenue by Business Segmentation 2013
  • Exhibit 66: Sanofi SA: Revenue by Business Segmentation 2012 and 2013 (US$ million)
  • Exhibit 67: Sanofi SA: Sales Revenue by Geographical Segmentation 2013
Back to Top